102 related articles for article (PubMed ID: 25958927)
21. CPU 86017, p-chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway.
Zhang TT; Cui B; Dai DZ; Su W
Acta Pharmacol Sin; 2005 Nov; 26(11):1309-16. PubMed ID: 16225752
[TBL] [Abstract][Full Text] [Related]
22. Effect of all-trans retinoic acids (ATRA) on the expression of α-smooth muscle actin (α-SMA) in the lung tissues of rats with pulmonary arterial hypertension (PAH).
Xin Y; Lv JQ; Wang YZ; Zhang J; Zhang X
Genet Mol Res; 2015 Nov; 14(4):14308-13. PubMed ID: 26600489
[TBL] [Abstract][Full Text] [Related]
23. [Pathophysiological characteristics of rat pulmonary hypertension and cor pulmonale induced by monocrotaline].
Li JS; Lng CL; Cui WY; Wang H
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2012 May; 28(3):193-6. PubMed ID: 22860411
[TBL] [Abstract][Full Text] [Related]
24. Basic fibroblast growth factor alterations during development of monocrotaline-induced pulmonary hypertension in rats.
Arcot SS; Fagerland JA; Lipke DW; Gillespie MN; Olson JW
Growth Factors; 1995; 12(2):121-30. PubMed ID: 8679246
[TBL] [Abstract][Full Text] [Related]
25. Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension.
Zimmer A; Teixeira RB; Bonetto JH; Siqueira R; Carraro CC; Donatti LM; Hickmann A; Litvin IE; Godoy AE; Araujo AS; Colombo R; Belló-Klein A
Mol Cell Biochem; 2017 May; 429(1-2):73-89. PubMed ID: 28181133
[TBL] [Abstract][Full Text] [Related]
26. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
27. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
Shen L; Shen J; Pu J; He B
Cell Biochem Biophys; 2011 Sep; 61(1):23-31. PubMed ID: 21327581
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
Zhang Y; Xie X; Zhu Y; Liu L; Feng W; Pan Y; Zhai C; Ke R; Li S; Song Y; Fan Y; Fan F; Wang X; Li F; Li M
Exp Lung Res; 2015; 41(8):435-43. PubMed ID: 26317171
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
Voelkel NF; Tuder RM; Bridges J; Arend WP
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
[TBL] [Abstract][Full Text] [Related]
30. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats.
Tang B; Chen GX; Liang MY; Yao JP; Wu ZK
Int J Cardiol; 2015 Feb; 180():134-41. PubMed ID: 25438234
[TBL] [Abstract][Full Text] [Related]
31. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Liu H; Liu ZY; Guan Q
Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):608-13. PubMed ID: 17670742
[TBL] [Abstract][Full Text] [Related]
32. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Zopf DA; das Neves LA; Nikula KJ; Huang J; Senese PB; Gralinski MR
Eur J Pharmacol; 2011 Nov; 670(1):195-203. PubMed ID: 21914448
[TBL] [Abstract][Full Text] [Related]
33. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.
Kishimoto Y; Kato T; Ito M; Azuma Y; Fukasawa Y; Ohno K; Kojima S
J Thorac Cardiovasc Surg; 2015 Sep; 150(3):645-54.e3. PubMed ID: 26095621
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
35. Beneficial effects of γ-aminobutyric acid on right ventricular pressure and pulmonary vascular remodeling in experimental pulmonary hypertension.
Suzuki R; Maehara R; Kobuchi S; Tanaka R; Ohkita M; Matsumura Y
Life Sci; 2012 Oct; 91(13-14):693-8. PubMed ID: 22542556
[TBL] [Abstract][Full Text] [Related]
36. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade.
Jasmin JF; Cernacek P; Dupuis J
Clin Sci (Lond); 2003 Dec; 105(6):647-53. PubMed ID: 12823096
[TBL] [Abstract][Full Text] [Related]
37. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
38. Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension.
Gubrij IB; Pangle AK; Pang L; Johnson LG
PLoS One; 2016; 11(1):e0147827. PubMed ID: 26815432
[TBL] [Abstract][Full Text] [Related]
39. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.
Mei Y; Jin H; Tian W; Wang H; Wang H; Zhao Y; Zhang Z; Meng F
Pulm Pharmacol Ther; 2011 Aug; 24(4):386-93. PubMed ID: 21396478
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats.
Nakazawa H; Hori M; Ozaki H; Karaki H
Br J Pharmacol; 1999 Nov; 128(5):1098-104. PubMed ID: 10556948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
